Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03697109 · ClinicalTrials.gov registry record · Phase 3

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

A Phase 3 study of Cushing Syndrome, sponsored by Corcept Therapeutics.

Completed
Registry status
Phase 3
Development phase
152
Enrollment target
20
Study locations

NCT03697109 is a Phase 3 study of Cushing Syndrome that has completed, run by Corcept Therapeutics. The registered enrollment target is 152 participants, roughly in line with the 163-participant average among 9 other Cushing Syndrome trials with a reported enrollment target. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03697109, a Phase 3 study of Cushing Syndrome, has completed, sponsored by Corcept Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (DM/IGT) and/or uncontrolled hypertension (HTN).

Conditions Studied

Cushing Syndrome

Interventions

  • OTHER Placebo
  • DRUG Relacorilant

Study Locations (20)

New York

  • Site 8 - Albany
  • Site 6 - Jamaica
  • Site 57 - New York
  • Site 35 - New York
  • Site 39 - New York

California

  • Site 36 - Los Angeles
  • Site 68 - Torrance

Arizona

  • Site 21 - Phoenix

Florida

  • Site 10 - Miami

Georgia

  • Site 14 - Atlanta

Illinois

  • Site 41 - Chicago

Indiana

  • Site 7 - Indianapolis

Louisiana

  • Site 2 - Metairie

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2018-11-15
Est. Completion 2024-04-15
Phase Phase 3

Sponsor

Corcept Therapeutics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03697109

The ClinicalTrials.gov registry entry for NCT03697109 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 163-participant average among 9 other Cushing Syndrome trials with a reported enrollment target. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cushing Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03697109 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT03697109 about?

NCT03697109 is a clinical study titled "A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome". This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (DM/IGT) and/or uncontrolled hyper...

What is the current status of trial NCT03697109?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2018-11-15. Estimated completion is 2024-04-15.

What conditions does trial NCT03697109 study?

This clinical trial studies the following conditions: Cushing Syndrome.

What interventions are being tested in trial NCT03697109?

The interventions under investigation include: Placebo (OTHER), Relacorilant (DRUG).

Who is sponsoring clinical trial NCT03697109?

This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03697109 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cushing Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cushing Syndrome

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.